Close
Achema middle east
swop processing & packaging

Glenmark announces the Discovery of a novel chemical entity ‘GRC 17536’, a potential first-in-class molecule globally

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Glenmark Pharmaceuticals announced the discovery of a Novel Chemical Entity(NCE) ‘GRC 17536’. The new NCE program is targeting TRPA1 recept or antagonists for pain and respiratory disorders. TRPA1 belongs to Transient Receptor Potential
(TRP) family of ion channels, which have generated a lot of interest as pain targets due to their
distinguishing role in peripheral and/or central pain signal transmission.

Glenmark has selected a lead molecule named GRC 17536 which is currently finishing up Phase 1
enabling GLP studies. Preclinical studies have been completed and Glenmark plans to file the
Phase 1 application in January 2011. This is another potential first-in-class molecule globally for
Glenmark

Commenting on this discovery, Glenn Saldanha, CEO & MD, Glenmark Pharmaceuticals ltd
mentioned “We are glad to announce our third novel molecule discovery in the TRP space. Both
our earlier TRP molecules i.e. TRPV1 and TRPV3 resulted in outlicensing deals for the company.
GRC 17536 which is a TRPA1 receptor antagonist is another potential first-in-class globally and
we are encouraged by the results shown by the molecule in animal studies. GRC 17536 is highly
selective even when compared with other TRPs and can be administered orally”

 

Latest stories

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »